Feed SRTS
SR

Sensus Healthcare, Inc.

SRTS · NASDAQ

$3.07 +0.33% (+$0.01)
1M -12.61%
Market Cap $50.5M
P/E Ratio -
Div. Yield -
ROE 34.09%

Bulios Fair Price

$2.11

31.3% downside

Current Price

$3.07

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SRTS is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
80 /100
Cheap
P/B 1.37x
P/S 2.89x
EV/EBITDA N/A
Growth
6 /100
Declining
Book val. growth 0.02%
Rev. growth 14.86%
FCF growth N/A
Profitability
14 /100
Weak
Net margin 88.45%
Op. margin 75.72%
FCF margin 39.76%
Quality
5 /100
Poor
ROE 34.09%
ROA 37.53%
Asset turnover 0.42x
Debt
100 /100
Low
Current ratio 8.71x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
18 /100
Unstable
Rev. volatility 64.34%
EPS volatility 828.90%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SRTS
Online

About the company

Sensus Healthcare, Inc. (SRTS) is a company specializing in the development and provision of advanced technologies for the treatment of cancer and dermatological conditions. With over a decade of history, Sensus Healthcare focuses on innovative approaches, such as low-dose radiation therapy, that selectively target tumor cells and minimize effects on surrounding healthy tissues. Their technologies offer patients and physicians alternative treatment options with an emphasis on effectiveness and reduced invasiveness. Sensus Healthcare, Inc. (SRTS) contributes to the advancement of sophisticated treatment methods and the improvement of quality of life for patients with cancer and dermatological conditions. Sensus Healthcare, Inc. (SRTS) shares could be suitable for investors who want to support innovations in oncological and dermatological treatment and contribute to progress in therapeutic approaches.

Sector

Healthcare

Industry

Medical - Devices

CEO

Joseph C. Sardano

Employees

60

Headquarters

Boca Raton

Upcoming events

05 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.